ORTEC
16.1.2024 15:31:30 CET | Business Wire | Press release
ORTEC, a global provider of decision support software and data science capabilities, is pleased to announce a partnership with investment firm Battery Ventures to accelerate its growth ambitions. This strategic partnership, including a significant investment by Battery, marks a key moment in ORTEC’s existence and positions the company to increase its impact on customers and in core markets globally. With this partnership, ORTEC will be able to further strengthen its leadership position in the US and Europe in the field of supply chain, workforce-management and data science & consulting.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240116805637/en/
Michael van Duijn (ORTEC CEO) and Zak Ewen (Partner Battery Ventures) (Photo: Business Wire)
Improving the world through data and mathematics
The ORTEC journey started in the early 1980s, when a few passionate Dutch students wanted to show the world the value of mathematics by creating long-term sustainable growth for organizations and society. Specifically, the company’s initial consulting business helped customers leverage data and mathematical models to solve operational problems. Over time, the company developed commercial products that help large enterprises address complex logistical challenges such as last-mile fleet dispatch and route planning; pallet-load planning and optimization; and advanced workforce scheduling and resource planning.
Now, more than 40 years later, ORTEC delivers solutions to over 1,200 customers worldwide to improve business results and make a positive impact on the world. Customers include ASML, Heineken, Coca-Cola Enterprises, Procter & Gamble, Shell, Waitrose, Albert Heijn, G4S, Sodexo and Tesco.
In partnership with Battery, going forward, ORTEC will offer products and services through three new divisions that focus on logistics and routing solutions, workforce-management solutions, and data science and consulting. Battery, which was founded in 1983, is a longtime, global software investor that has made more than 500 investments over the last four decades.
“We are very pleased that Battery Ventures joins ORTEC as a strategic partner. With their knowledge, experience, and network, we can further drive innovation, expand our market reach and create additional impact for our customers,” said Michael van Duijn, ORTEC’s chief executive. “I am proud of the great company we are today and the amazing group of talented employees that create impact for our customers day in and day out. It makes me excited that with this partnership, we have the ingredients to make a more positive impact on the world.”
Shared commitment to long-term growth
The agreement between ORTEC and Battery Ventures highlights a shared commitment to drive innovation, deliver exceptional value to customers, and achieve long-term impact growth. Both parties are confident that the partnership will pave the way for ORTEC to expand its strong position as a leading provider of optimization technology built to solve complex operational challenges in an increasingly data-driven world.
“We’ve gotten to know ORTEC and its founding team over a period of more than 10 years, and during that time we’ve watched the business transform from a consulting-led business into a commercial software company serving the world’s most sophisticated and complex enterprises,” said Zak Ewen, a Battery partner based in London, who joins ORTEC’s board. “Now we’re excited to formally partner with Michael, Aart, Gerrit and the rest of the team to further accelerate the company’s mission.”
Moving forward, ORTEC founders Aart van Beuzekom and Gerrit Timmer remain part of the board and will continue to take care of ORTEC and its future.
About ORTEC
For more than 40 years ORTEC has been supporting many of the world’s best-run organizations to make better data-driven decisions. Our decision support software and data science capabilities enable our customers to improve their business results and make a positive impact on the world. With our 1,000 employees across 13 countries, we help over 1,200 leading customers worldwide to make better choices in an ever-changing environment. Discover more at www.ortec.com.
About Battery Ventures
Battery partners with exceptional founders and management teams developing category-defining businesses in markets including software and services, enterprise infrastructure, online marketplaces, healthcare IT and industrial technology. Founded in 1983, the firm backs companies at all stages, ranging from seed and early to growth and buyout, and invests globally from six strategic locations: Boston; San Francisco and Menlo Park, Calif.; Herzliya, Israel; London; and New York. Follow the firm on X @BatteryVentures, visit our website at www.battery.com and find a full list of Battery's portfolio companies.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240116805637/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Daiichi Sankyo Appoints Markus Kosch to Lead Europe Business as Part of New Commercialization Organization24.8.2026 10:00:00 CEST | Press release
Daiichi Sankyo (TSE: 4568) today announced the appointment of Markus Kosch, MD, as Head of Europe Business, effective April 1, 2027. In this role, he will lead the company's European business within the new globally integrated Commercialization Unit and serve as General Manager of Daiichi Sankyo Europe GmbH, with legal responsibility for the company in Europe. The appointment reflects the next phase of growth of Daiichi Sankyo under its Five-Year Business Plan and the establishment of a new Commercialization Unit. Within this new structure, Markus Kosch will bring together the Oncology and Specialty businesses in Europe under one integrated leadership model to help bring innovative medicines to more patients across the region. For the past five years, Markus Kosch has led the Daiichi Sankyo Oncology Business Division in Europe and Canada, overseeing a period of significant growth and preparing the organization for an increasingly expanding oncology portfolio. Prior to joining Daiichi S
European Commission Approves DAYBU® (trofinetide) as the First and Only Treatment for Neurobehavioral Symptoms of Rett Syndrome in the European Union24.8.2026 09:01:00 CEST | Press release
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the European Commission (EC) has granted marketing authorization for DAYBU (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older, making it the first and only treatment approved for Rett syndrome in the European Union (EU). “The approval of DAYBU marks a significant milestone for the Rett syndrome community in the EU and advances our mission to bring this innovative treatment to patients and families who have long faced a profound unmet medical need,” said Catherine Owen Adams, Acadia’s Chief Executive Officer. “For people living with Rett syndrome, a devastating rare neurodevelopmental disorder, there have been no approved treatment options in the EU. We are proud to make DAYBU available and look forward to supporting patients, caregivers, and healthcare providers gain access to treatment." The DAYBU marketing authorization in the EU is prim
ORZEYFUL (oveporexton) Approved in Japan as the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 124.8.2026 08:36:00 CEST | Press release
Discovered by Takeda in Japan, ORZEYFUL has the Potential to Redefine Care Beyond Individual Symptom Management for Adults Living with Narcolepsy Type 1 (NT1) Landmark Phase 3 Studies Demonstrated Significant and Meaningful Improvements Across the Full Range of NT1 Symptoms Evaluated in Clinical Trials Compared to Placebo Milestone Marks Third Major Regulatory Approval Secured for ORZEYFUL Around the World Takeda (TOKYO:4502/NYSE:TAK) announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) approved the use of ORZEYFUL (oveporexton) for the treatment of narcolepsy type 1 (NT1, narcolepsy with cataplexy) in adults. ORZEYFUL is a first-in-class oral orexin receptor 2 (OX2R) agonist and the only medicine indicated in Japan to treat the disease holistically rather than individual symptoms. The discovery of this new class of medicine originated in Takeda's laboratories in Japan. Takeda is proceeding with launch preparations and expects to make ORZEYFUL available as quickly
Fasset Hits $1B Valuation as SBI Group Leads $68M Series C to Scale AI-Powered Stablecoin Neobanking24.8.2026 08:03:00 CEST | Press release
Round led by SBI Group follows $51 million Series B raise in May 2026, marking ascent as one of the fastest-growing neobanking platforms. Capital will expand Own Network and deepen AI across stablecoin settlement, tokenization, and corridor banking. Fasset now processes more than $40 billion in annualized transaction volume, serving 3 million+ wallets and more than 1,000 enterprises across 125 countries. Fasset, the AI-powered stablecoin neobanking platform, today announced it has raised $68 million in Series C funding at a $1 billion valuation. The financing was led by SBI Group and follows Fasset’s $51 million Series B earlier this year, which brought Speedinvest onto the cap table alongside a group of strategic investors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260823503947/en/ Mohammad Raafi Hossain, Co-Founder and CEO, Fasset The new capital will support the expansion of Own Network, Fasset’s regulated financial
Zanders Expands DACH Region with New Office in Vienna, Austria24.8.2026 07:11:00 CEST | Press release
Zanders, the global treasury, risk, and technology consultancy, today announced a significant expansion of its DACH region with the opening of a new office in Vienna. The move builds on Zanders' continued growth across Germany, Austria, and Switzerland, and marks another step in the firm's strategy of deepening its presence in the markets where client demand for specialized treasury, risk, and corporate finance advisory is growing fastest. DACH has been one of Zanders' priority regions for several years, with the firm steadily expanding its team and client base across Germany and Switzerland. Austria represents a natural next step in that growth: in conversations with clients in the market, Zanders has seen growing interest in treasury transformation and financing support, as companies work through interest rate volatility, refinancing needs, and a broader shift toward more digitized, centralized treasury operations. The new Vienna office allows Zanders to be closer to clients' operati
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom